News For THOR From The Last 14 Days Check below for free stories on THOR the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
August 25, 2010
|
| 13:58 EDT |  | THOR |
|
|
August 24, 2010
|
| 09:00 EDT |  | THOR |
| theflyonthewall.com: | On The Fly: Analysts Initiation Summary | | MOST NOTEWORTHY: Everest RE Group (RE), Retailers and SMART Technologies (SMT) were today's noteworthy initiations: Deutsche Bank started Everest RE Group with a Buy rating and $92 target. Janney Montgomery initiated Aeropostale (ARO), Hot Topic (HOTT) and Bebe (BEBE) with Neutral ratings and price targets of $25, $5 and $6, respectively, and Ann Taylor (ANN) and J. Crew (JCG) with Buy ratings and price targets of $19 and $41, respectively. Morgan Stanley initiated SMART Technologies with an Overweight rating and $17 target. Shares were also started at Piper Jaffray with an Overweight rating and $16 target, at Deutsche Bank with a Buy rating and $20 target and with an Outperform rating and $15 target at Credit Suisse...OTHER INITIATIONS: Thoratec (THOR) was initiated with a Buy rating and $50 target at Madison Williams. NetLogic (NETL) was initiated with an Equal Weight rating at Morgan Stanley. Dana Holding (DAN) was reinstated with a Buy rating and $17 target at KeyBanc. :theflyonthewall.com |
| | 06:30 EDT |  | THOR |
|
|
August 20, 2010
|
| 10:11 EDT |  | THOR |
| theflyonthewall.com: | Wedbush says Medicare decision positive for ventricular device makers | | In a note to investors, Wedbush analysts Dr. Duane Nash and Akiva Felt wrote that weakness in providers of left ventricular assist devices - including Thoratec (THOR), HeartWare (HTWR), and WorldHeart (WHRT) - could create an attractive entry point for investors. Although Medicare decided not to expand reimbursement for the devices to Class IIIB patients as anticipated by Wedbush, the firm believes that the agency did make other changes that are positive for the device makers. These changes will allow left ventricular assist devices to be implanted more quickly and with less paperwork ,according to Wedbush. The firm expects HeartWare to rebound most quickly, while it recommends Thoratec for longer-term investors. Wedbush sees WorldHeart as attractive, but riskier. In early trading, Thoratec gained 1.50% to $34.40, while WorldHeart was flat at $2.27 and HeartWare fell 1.33% to $63.58. :theflyonthewall.com |
| | 08:52 EDT | | THOR |
| theflyonthewall.com: | CMS decision on LVADs could bring buying opportunities, says Wedbush | | Wedbush notes that the CMS said last night it is not expanding left ventricular assist device, or LVAD, reimbursement to include to Class IIIB patients. However, the firm points out CMS did make positive changes to the objective criteria. Wedbush recommends using any weakness in shares of Thoratec (THOR), HeartWare (HTWR), and World Heart (WHTR) following the news as buying opportunities. :theflyonthewall.com |
|
|
|
Subscribe for More Information